For the quarter ending 2025-09-30, MLYS had $115,809K increase in cash & cash equivalents over the period. -$28,872K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -36,932 | -85,485 |
| Accretion of discount on held-to-maturity securities | 2,396 | 3,275 |
| Stock-based compensation | 5,841 | 8,198 |
| Depreciation and amortization | 15 | 31 |
| Accrued interest receivable | -10 | -5 |
| Prepaid, other current assets, and other assets | -3,560 | 2,658 |
| Accounts payable and accrued liabilities | 1,030 | 7,528 |
| Net cash used in operating activities | -28,872 | -75,656 |
| Purchases of marketable securities | 300,507 | 245,757 |
| Maturities of marketable securities | 150,000 | 110,000 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities | -150,507 | -135,757 |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-Public Offering September2025 | 270,200 | - |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-Public Offering | - | 188,880 |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-Public Offering March2025 | 188,880 | - |
| Proceeds from issuance of common stock in public offering, net of offering costs and pursuant to atm agreement, net of issuance costs-At The Market | 18,393 | 8,943 |
| Proceeds from stock option exercises | 6,624 | 1,202 |
| Proceeds from issuance of common stock for cash under employee stock purchase plan | 0 | 142 |
| Payment of shelf offering costs | 29 | 57 |
| Proceeds from issuance of common stock and pre-funded warrants in a private placement offering, net of offering costs | 0 | 0 |
| Net cash provided by financing activities | 295,188 | 199,110 |
| Net increase in cash and cash equivalents | 115,809 | -12,303 |
| Cash and cash equivalents at beginning of period | 114,091 | - |
| Cash and cash equivalents at end of period | 217,597 | - |
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)